Involvement of GLUT1-mediated glucose transport and metabolism in gefitinib resistance of non-small-cell lung cancer cells

Use of epidermal growth factor receptor (EGFR) inhibitors represented by gefitinib and erlotinib has become the standard of treatment for non-small-cell lung cancers (NSCLCs) with activating EGFR mutations. However, the majority of NSCLCs, which overexpress EGFR without such mutations, are resistant...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Shuhei, Okada, Masashi, Takeda, Hiroyuki, Kuramoto, Kenta, Sanomachi, Tomomi, Togashi, Keita, Seino, Shizuka, Yamamoto, Masahiro, Yoshioka, Takashi, Kitanaka, Chifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135698/
https://www.ncbi.nlm.nih.gov/pubmed/30220973
http://dx.doi.org/10.18632/oncotarget.25994

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135698/
https://www.ncbi.nlm.nih.gov/pubmed/30220973
http://dx.doi.org/10.18632/oncotarget.25994

Ejemplares similares